Lexicon Pharmaceuticals vs Tonix Pharmaceuticals
LXRX and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and TNXP compare
Lexicon Pharmaceuticals is the larger company, worth 16 times as much as Tonix Pharmaceuticals ($792M against $50.4M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (196% versus −29.0% for Lexicon Pharmaceuticals).
Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −147% compared with −549% at Tonix Pharmaceuticals.
Tonix Pharmaceuticals scores higher on the StockData Score (10 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $792M | $50.4M |
| Share price | $1.78 | $2.94 |
| Change, 1 year | 19.5% | −81.5% |
| Change, 5 years | −62.4% | −100.0% |
| Beta (5Y) | 0.01 | 0.75 |
| Employees | 81 | 142 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.1× | 1.7× (better) |
| P/B | 4.5× | 0.2× (better) |
| FCF yield | – | −314% |
| Fair value | $0.950 | $16.91 |
| Margin of safety | −87.4% | 82.6% (better) |
| Growth | ||
| Revenue growth (TTM) | −29.0% | 196% (better) |
| Revenue growth, 5Y average | 15.7% | – |
| Profitability | ||
| Gross margin | 99.1% (better) | 83.8% |
| Operating margin | −131% (better) | −568% |
| Net margin | −147% (better) | −549% |
| FCF margin | – | −543% |
| Return on equity | −40.2% (better) | −81.8% |
| Return on invested capital | −163% (better) | −298% |
| Financial health | ||
| Debt / equity | 0.29 (better) | 0.00 |
| Current ratio | 13.37 (better) | 6.61 |
| Altman Z-score | −4.87 (better) | −5.42 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −427% |
| Shareholder yield | 0.00% (better) | −427% |
| Ownership | ||
| Held by institutions | 81.9% | 54.6% |
| Held by insiders | – | 0.27% |
| Insider net buying, 12 months | $2.8M (better) | $479K |
| Short interest, % of float | – | 19.4% |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.